Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New findings on structure and function of prostate-specific membrane antigen

Dec. 17, 2003

Valera files Vantas NDA

Dec. 17, 2003

Independent committee recommends early end to phase III Velcade trial

Dec. 17, 2003

Japanese rights to bevacizumab and pertuzumab licensed to Chugai

Dec. 17, 2003

Targent acquires dibromodulcitol

Dec. 17, 2003

Novacea licenses North American rights to AQ4N

Dec. 17, 2003

Praecis collaborates with NCI on PPI-2458

Dec. 16, 2003

Avanir and Peregrine execute license agreement for antibody

Dec. 16, 2003

Phase I trial commences for CNTO-95

Dec. 16, 2003

Monoclonal antibody targeting CD44 induces differentiation and apoptosis in AML cells

Dec. 15, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...